Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.

Oasmia in brief

Our vision is to improve the quality for treatment of severe diseases. Researching and developing next generation medicines, our focus is on advancing oncology treatments.

Research

At Oasmia, we’re developing the next generation of drugs with focus on oncology.

Production

At our EMA and FDA-approved production facility we manufacture drugs for both clinical trials and sales.

Our technology

Our nanoparticle platform XR17 possesses unique properties to improve current and future medicines.

The Share

News

Conversion of SEK 42M convertible loan in Oasmia

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) announce that the convertible loan of SEK 42,000,193.20 (series 2017:1) will be fully converted to shares.
Read more

Oasmia completes set-off private placements of new convertibles in the total amount of SEK 26 million with conversion rate of SEK 8.00

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount SEK 26,000,000 through a dir...
Read more

Oasmia successfully completes private placements of new convertibles in the total amount of SEK 42 million with conversion rate of SEK 5.95

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount SEK 42,000,193 and placed wi...
Read more
To news archive